This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
According to analyst Eric Joseph, Beam is at the frontier of a rising theme for investors this year: therapeutics.
Source link
- Israeli intelligence accuses UNRWA staff of kidnap, seizing body
- UN chief to meet with major donors of Palestinian refugee agency amid funding crisis
